Literature DB >> 18391979

Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis.

L van der Weyden1, M J Arends, O M Dovey, H L Harrison, G Lefebvre, N Conte, F V Gergely, A Bradley, D J Adams.   

Abstract

Promoter methylation of the RAS-association domain family 1, isoform A gene (RASSF1A) is one of the most frequent events found in human tumours. In this study we set out to test the hypothesis that loss of Rassf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate intestinal tumourigenesis using the Apc-Min (Apc(Min/+)) mouse model, as mutational or deletional inactivation of APC is a frequent early event in the genesis of intestinal cancer. Further, loss of RASSF1A has also been reported to occur in premalignant adenomas of the bowel. RASSF1A has been implicated in an array of pivotal cellular processes, including regulation of the cell cycle, apoptosis, microtubule stability and most recently in the beta-catenin signalling pathway. By interbreeding isoform specific Rassf1a knockout mice with Apc(+/Min) mice, we showed that loss of Rassf1a results in a significant increase in adenomas of the small intestine and accelerated intestinal tumourigenesis leading to the earlier death of adenocarcinoma-bearing mice and decreased overall survival. Comparative genomic hybridization of adenomas from Rassf1a(-/-); Apc(+/Min) mice revealed no evidence of aneuploidy or gross chromosomal instability (no difference to adenomas from Rassf1a(+/+); Apc(+/Min) mice). Immunohistochemical analysis of adenomas revealed increased nuclear beta-catenin accumulation in adenomas from Rassf1a(-/-); Apc(+/Min) mice, compared to those from Rassf1a(+/+); Apc(+/Min) mice, but no differences in proliferation marker (Ki67) staining patterns. Collectively these data demonstrate cooperation between inactivation of Rassf1a and Apc resulting in accelerated intestinal tumourigenesis, with adenomas showing increased nuclear accumulation of beta-catenin, supporting a mechanistic link via loss of the known interaction of Rassf1 with beta-TrCP that usually mediates degradation of beta-catenin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391979      PMCID: PMC3706934          DOI: 10.1038/onc.2008.94

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Cancer: Chromosome defects in the colon.

Authors:  D M Livingston
Journal:  Nature       Date:  2001-03-29       Impact factor: 49.962

Review 2.  Wnt signalling in stem cells and cancer.

Authors:  Tannishtha Reya; Hans Clevers
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

3.  Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human.

Authors:  Paola Alberici; Emma de Pater; Joana Cardoso; Mieke Bevelander; Lia Molenaar; Jos Jonkers; Riccardo Fodde
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Knockout mouse models to study Wnt signal transduction.

Authors:  Renée van Amerongen; Anton Berns
Journal:  Trends Genet       Date:  2006-10-11       Impact factor: 11.639

5.  The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis.

Authors:  L van der Weyden; K K Tachibana; M A Gonzalez; D J Adams; B L Ng; R Petty; A R Venkitaraman; M J Arends; A Bradley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Tumor susceptibility of Rassf1a knockout mice.

Authors:  Stella Tommasi; Reinhard Dammann; Zhongqiu Zhang; Yian Wang; Limin Liu; Walter M Tsark; Sharon P Wilczynski; Jie Li; Ming You; Gerd P Pfeifer
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

7.  Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice.

Authors:  A M Carothers; K A Melstrom; J D Mueller; M J Weyant; M M Bertagnolli
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

8.  Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

Authors:  L K Su; K W Kinzler; B Vogelstein; A C Preisinger; A R Moser; C Luongo; K A Gould; W F Dove
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

9.  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse.

Authors:  A R Moser; H C Pitot; W F Dove
Journal:  Science       Date:  1990-01-19       Impact factor: 47.728

10.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients.

Authors:  I Nishisho; Y Nakamura; Y Miyoshi; Y Miki; H Ando; A Horii; K Koyama; J Utsunomiya; S Baba; P Hedge
Journal:  Science       Date:  1991-08-09       Impact factor: 47.728

View more
  13 in total

1.  Safeguarding genome stability: RASSF1A tumor suppressor regulates BRCA2 at stalled forks.

Authors:  Dafni Eleftheria Pefani; Eric O'Neill
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.

Authors:  Thibaut Barnoud; M Lee Schmidt; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Lett       Date:  2017-04-26       Impact factor: 8.679

3.  Megaoesophagus in Rassf1a-null mice.

Authors:  Louise van der Weyden; Lisa Happerfield; Mark J Arends; David J Adams
Journal:  Int J Exp Pathol       Date:  2009-04       Impact factor: 1.925

4.  The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.

Authors:  Mirco Menigatti; Elisa Cattaneo; Jacob Sabates-Bellver; Valery V Ilinsky; Philip Went; Federico Buffoli; Victor E Marquez; Josef Jiricny; Giancarlo Marra
Journal:  Mol Cancer       Date:  2009-12-16       Impact factor: 27.401

5.  Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma.

Authors:  Tao Wang; Hongli Liu; Yeshan Chen; Wei Liu; Jing Yu; Gang Wu
Journal:  J Exp Clin Cancer Res       Date:  2009-12-30

6.  Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis.

Authors:  Louise van der Weyden; Angelos Papaspyropoulos; George Poulogiannis; Alistair G Rust; Mamunur Rashid; David J Adams; Mark J Arends; Eric O'Neill
Journal:  Cancer Res       Date:  2012-06-18       Impact factor: 12.701

7.  The SARAH Domain of RASSF1A and Its Tumor Suppressor Function.

Authors:  Claudia Dittfeld; Antje M Richter; Katrin Steinmann; Antje Klagge-Ulonska; Reinhard H Dammann
Journal:  Mol Biol Int       Date:  2012-04-09

8.  Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.

Authors:  Nikola Vlahov; Simon Scrace; Manuel Sarmiento Soto; Anna M Grawenda; Leanne Bradley; Daniela Pankova; Angelos Papaspyropoulos; Karen S Yee; Francesca Buffa; Colin R Goding; Paul Timpson; Nicola Sibson; Eric O'Neill
Journal:  Curr Biol       Date:  2015-11-05       Impact factor: 10.834

9.  The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury.

Authors:  Marilyn Gordon; Mohamed El-Kalla; Yuewen Zhao; Yahya Fiteih; Jennifer Law; Natalia Volodko; Anwar Anwar-Mohamed; Anwar Mohamed; Ayman O S El-Kadi; Lei Liu; Jeff Odenbach; Aducio Thiesen; Christina Onyskiw; Haya Abu Ghazaleh; Jikyoung Park; Sean Bong Lee; Victor C Yu; Carlos Fernandez-Patron; R Todd Alexander; Eytan Wine; Shairaz Baksh
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  RASSF1A Site-Specific Methylation Hotspots in Cancer and Correlation with RASSF1C and MOAP-1.

Authors:  Natalia Volodko; Mohamed Salla; Alaa Zare; El-Arbi Abulghasem; Krista Vincent; Matthew G K Benesch; Todd P W McMullen; Oliver F Bathe; Lynne Postovit; Shairaz Baksh
Journal:  Cancers (Basel)       Date:  2016-06-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.